$ZTS

The Bull Case for Zoetis Stock as Michael Burry Doubles Down

Zoetis shares fell 47.6% over 52 weeks and 38.6% YTD, but are up 8.16% from a June 30 52-week low of $71.47. In Q1 2026, revenue rose 3% to $2.26B and non-GAAP EPS rose 9% to $1.53, with U.S. revenue down 8% YOY. Guidance: revenue $9.68B-$9.96B, EPS $6.85-$7.00. Analysts’ consensus target is $107.19.

Original reporting
Published Aug 5, 2026, 6:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Bull Case for Zoetis Stock as Michael Burry Doubles Down — source image
Decision brief

The 30-second read

$ZTSNeutralLow
01

Why it matters

Guidance ranges and segment mix can influence earnings estimate paths into the Aug. 6 EPS release, but the article itself is primarily an editorial bull-case with analyst target changes rather than a new disclosure.

02

Market read

Traders may use the guidance ranges and the Aug. 6 EPS timing to position for estimate revisions, but the piece does not introduce a new earnings print or deal.

03

What to watch

Livestock growth is a bright spot, yet the article does not quantify whether it offsets broader pet-owner price sensitivity sustainably into the next quarters.

Relevance 4/10Novelty 4/10Timing: ahead of Aug. 6 pre-market EPS report

Background

Zoetis shares have fallen sharply over 52 weeks and YTD, and the article discusses valuation, Q1 operating conditions, and updated guidance.

Company-level read

Ticker impact

$ZTSNeutralMedium confidence
Context

Zoetis updated FY revenue guidance to $9.68B-$9.96B and EPS to $6.85-$7.00 amid flat organic growth and a weaker U.S. segment.

Expected impact

Likely modest volatility around the Aug. 6 EPS report as investors weigh guidance range versus moderated analyst targets.

Evidence & confidence

It provides concrete guidance ranges and segment performance, but it is framed as a bull-case/analyst roundup rather than a fresh earnings print or new company action.

Market effects

Healthcare/pet and animal health sentiment may remain mixed if U.S. demand softness persists while international offsets.

U.S. weakness versus international strength highlights regional demand divergence for animal health names.

Limited, as the piece is company-specific and does not introduce cross-sector regulatory or macro shocks.

Counterpoint

The bull case leans on valuation and consensus upside, but the text flags flat organic growth and a U.S. revenue decline, which could cap multiple expansion.

Key entities

  • Zoetis

    Animal health company discussed for Q1 performance and updated FY guidance, with an upcoming Aug. 6 EPS release.

  • UBS

    Maintained Neutral and cut its price target to $85.

  • Morgan Stanley

    Maintained Buy and cut its price target to $99.

  • HSBC

    Kept Buy and cut its price target to $95.

Related articles

$ZTSMedAI 8/10

Zoetis Inc. Q2 2026 Earnings Call Summary

Zoetis reported U.S. revenue down 7% and U.S. Companion Animal down 11% in Q2 2026, citing fewer vet visits and heavier discounting by competitors. Full-year organic operational revenue guidance revised to a 3% to 1% decline. Diagnostics grew 12%. Zoetis plans continued gross-to-net promotions, FX headwinds of $60m to $65m, and a buyback over $550m.

$ZTSMed

Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations

Zoetis (NYSE:ZTS) reported Q2 CY2026 sales of $2.47 billion, flat year on year, and below market expectations. The company’s full-year revenue guidance midpoint of $9.22 billion was 5.4% below analysts’ estimates. Non-GAAP adjusted EPS was $1.87, up from $1.76, about in line with consensus.

$ZTSHighAI 9/10

Zoetis Slashes FY26 Outlook - Update

Zoetis (ZTS) reported Q2 results and cut its FY2026 guidance due to the current operating environment. It now expects EPS of $5.55 to $5.65 and adjusted EPS of $6.15 to $6.25 on revenue of $9.12B to $9.32B, with organic revenue down 3% to 1%. Prior outlook was higher. ZTS traded at about $76.00 premarket.

$ZTSHigh

Zoetis Inc. (ZTS): Results of Operations and Financial Condition

Zoetis Inc. (ZTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99q22026.htm EX-99.1 Document EXHIBIT 99.1 Zoetis Announces Second Quarter 2026 Results • Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis • Adjusted Net In